Skip to main content

Table 3 Medication use

From: Cognitive-behavioural therapy has no effect on disease activity but improves quality of life in subgroups of patients with inflammatory bowel disease: a pilot randomised controlled trial

  +CBT SC
  n (%)
  Baseline 6 months 12 months Baseline 6 months 12 months
n = 90 n = 51 n = 42 n = 84 n = 65 n = 64
Azathioprine 44 (49) 21 (41) 16 (38) 22 (26) 16 (25) 16 (25)
Mesalazine 25 (28) 11 (22) 10 (24) 32 (38) 20 (31) 22 (34)
Sulphasalazine 13 (14) 6 (12) 7 (16) 14 (17) 12 (18) 10 (15)
Corticosteroids 10 (11) 6 (12) 3 (7) 8 (9) 5 (8) 6 (9)
Adalimumab 10 (11) 7 (14) 2 (5) 6 (7) 4 (6) 4 (6)
Infliximab 10 (11) 8 (16) 5 (12) 5 (6) 5 (8) 6 (9)
Vedolizumab 3 (3) 1 (2) 1 (2) 1 (1) 0 0
Methotrexate 4 (4) 4 (8) 2 (5) 4 (5) 2 (3) 2 (3)
Mercaptopurine/thiopurine 2 (2) 2 (4) 5 (12) 4 (5) 0 5 (8)
Vitamins 28 (31) 12 (23) 6 (14) 23 (27) 12 (18) 11 (17)
Fish oil 17 (19) 12 (23) 9 (21) 11 (13) 9 (14) 6 (9)
Probiotics 11 (12) 5 (10) 5 (12) 7 (8) 6 (9) 6 (9)
Paracetamol 24 (27) 14 (27) 10 (24) 18 (21) 10 (15) 11 (17)
Codeine 10 (11) 3 (6) 4 (9) 4 (5) 4 (6) 3 (5)
Ibuprofen 6 (7) 2 (4) 2 (5) 3 (4) 1 (1) 1 (1)
Dextropropoxyphene 4 (4) 1 (2) 0 1 (1) 1 (1) 0
Antispasmodics 2 (2) 1 (2) 1 (2) 1 (1) 2 (3) 4 (6)
Morphine 1 (1) 0 0 2 (2) 0 1 (1)
Oxycodone hydrochloride 1 (1) 3 (6) 2 (2) 2 (2) 3 (5) 0
Tramadol 1 (1) 0 0 1 (1) 0 0
Naproxen 0 1 (2) 0 0 0 0
Medication for depression 24 (28) 14 (29) 10 (24) 20 (27) 12 (18) 12 (19)